We are live on ! Find out more

Amgen

AMGN

Market cap $249B

460.42 USD

+0.14

0.03%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

461.50

+1.08

0.23%

1 day

0.03%

5 days

-0.65%

1 month

14.36%

3 months

13.73%

6 months

39.05%

Year to date

40.53%

1 year

45.89%

5 years

117.83%

10 years

230.74%

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 31,500

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 55.3%

Neutral 29.8%

Negative 14.9%

The Motley Fool

Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.

Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?

REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY

Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease (ASCVD) and prior statin use.

REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY

Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data

Amgen Inc. (NASDAQ:AMGN) shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.

Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data

Zacks Investment Research

AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook

Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.

AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook

Zacks Investment Research

AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance

Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.

AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance

Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript

Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript

Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript

What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen NASDAQ: AMGN reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several late-stage programs. The company raised its full-year revenue and adjusted earnings outlook while highlighting growth in cardiovascular, bone health, inflammation, rare disease, oncology and biosimilar medicines.

What Amgen (AMGN) Said on Its Q3 Earnings Call

Zacks Investment Research

Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates

Amgen (AMGN) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $5.64 per share a year ago.

Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates

Investors Business Daily

Amgen, Up 41% This Year, Is Broadly Outperforming Its Peers. Here's What Its Earnings Say.

Amgen beat Wall Street's top- and bottom-line expectations late Tuesday, but there were puts and takes across the board.

Amgen, Up 41% This Year, Is Broadly Outperforming Its Peers. Here's What Its Earnings Say.

See News Rankings

Price charts implemented using Lightweight Charts™